Objective: Delayed thrombolytic therapy with recombinant tissue plasminogen activator (tPA) may exacerbate blood-brain barrier (BBB) breakdown after ischemic stroke and lead to catastrophic hemorrhagic transformation (HT). Rosiglitazone(RSG), a widely used antidiabetic drug that activates peroxisome proliferator-activated receptor-γ (PPAR-γ), has been shown to protect against cerebral ischemia through promoting poststroke microglial polarization toward the beneficial anti-inflammatory phenotype. However, whether RSG can alleviate HT after delayed tPA treatment remains unknown. In this study, we sort to examine the role of RSG on tPA-induced HT after stroke.
| INTRODUC TI ON
Tissue-type plasminogen activator (tPA) is the only FDA-approved drug therapy for acute ischemic stroke. [1] [2] [3] Unfortunately, the administration of tPA may increase the risk of hemorrhagic transformation(HT), especially when delayed beyond 4.5 hours after the onset of ischemia, [4] [5] [6] leading to poor clinical outcomes in stroke patients. [7] [8] [9] Accumulating evidence suggests that HT is associated with disruption of blood-brain barrier (BBB), which may occur early after stroke and largely limit the clinical use of tPA thrombolysis for stroke patients. 7, 10, 11 Thus, there is an unmet need for developing an adjuvant agent that could protect the BBB integrity and extend the therapeutic window of tPA to benefit more stroke patients for safe thrombolysis and better functional recovery. 12 Peroxisome proliferator-activated receptor-γ (PPAR-γ), a ligandactivated transcription factor belonging to the nuclear receptor superfamily, has been shown to orchestrate the microglia/macrophage phenotype switch from pro-inflammatory to anti-inflammatory phenotype, thus leading to inhibition of inflammation and tissue repair. [13] [14] [15] [16] Rosiglitazone(RSG), a widely used antidiabetic drug with potent PPAR-γ activating capacity, can protect against cerebral ischemia through its anti-inflammatory and anti-oxidant effect. [17] [18] [19] However, it remains unknown whether RSG can be used as an adjuvant agent to protect the BBB integrity, especially during tPA thrombolysis after stroke. In this study, we sought to assess the effects of RSG on the protection of BBB integrity in tPA-treated stroke mice and explore the underlying mechanism of RSG-afforded protection against tPA-induced HT after stroke.
| MATERIAL S AND ME THODS

| Murine model of transient focal ischemia
All animal experiments were approved by the Renji Hospital
Institutional Animal Care and Use Committee and performed in accordance with the Institutional Guide for the Care and Use of Laboratory Animals. Focal cerebral ischemia was produced by intraluminal occlusion of the left middle cerebral artery (MCA) with a nylon monofilament suture as originally described with slight modifications. 4, 20, 21 Male 2-to 3-month-old C57/B6 mice (25-30 g each)
were anesthetized with 1.5% isoflurane in a 30% O2/68.5% N2O mixture under spontaneous breathing. Rectal temperature was controlled at 37°C during and after surgery via a temperature-regulated heating pad. The animals underwent left MCA occlusion (MCAO) for 2 hours and then were reperfused by withdrawing the suture. After recovering from anesthesia, the animals were maintained in an airconditioned room at 25°C.
| Two-dimensional laser speckle imaging techniques
Cortical blood flow was monitored using the laser speckle technique as described previously. 22 Laser speckle perfusion images were obtained during middle cerebral artery occlusion and after reperfusion.
Cerebral blood flow changes were recorded over time and expressed as a percentage of contralateral-MCAO baselines.
| Reperfusion with tPA and Rosiglitazone administration
At 2 hours after suture occlusion,the right femoral vein was cannulated for tPA administration. Recombinant human tPA (Actilyse;
Boehringer Ingelheim) was intravenously administered at a dose of 10 mg/kg (10% as a bolus and 90% as a 30-minute infusion) using a syringe infusion pump after reperfusion. RSG (Sigma-Aldrich) was dissolved in dimethylsulfoxide and then further diluted in physiological saline (1:3 ratio), and was injected intraperitoneally (6 mg/kg) 1 hour before MCAO and at the time of tPA infusion. The animals that received administration of RSG or vehicle (25% dimethylsulfoxide) were assigned randomly to experimental groups. The optimal dose of the compound was administered as described before. 
| Measurements of infarct volume
For microtubule-associated protein 2 (MAP-2) staining, animals were sacrificed and perfused transcardiacally with 0.9% normal saline and 4% paraformaldehyde in PBS. Free-floating sections were prepared from the fixed and dehydrated brains and stained with MAP-2 Abs (Santa Cruz Biotechnology). Infarct volume was determined with NIH Image J (1.52a)
analysis by an observer "blinded" to the experimental group assignment.
| Cresyl violet staining
Cresyl violet (CV) staining was performed to determine changes in intracerebral hemorrhage volume. Brain slices were mounted and left to dry for 24 hours at 4°C. Then, they were placed in a staining cage to dry at room temperature for 2 minutes. The slices were placed into a CV stain (0.1%, Solarbio) for 1. 
| Flow cytometry
We homogenized the hemisphere ipsilateral to the infarct using a Neural Tissue Dissociation Kit (MACS) by the gentle MACS Dissociator following the manufacturer's instructions (Miltenyi Biotec, Germany). The monocyte-enriched population of cells was collected using a Percoll gradient. 24 Cells were stained with APC-Cy7-CD45 (BD Biosciences), FITC-CD11b (BD Biosciences), BV510-CD86
(BD Biosciences), APC-CD206 (Invitrogen), and the appropriate isotype controls (eBiosciences) following manufacturer's instructions, counted on the FACS Verse cell sorter (BD Biosciences) and analyzed using FlowJo software (TreeStar). We first evaluated the effect of RSG on HT using the suture MCAO followed by tPA intravenous infusion (10 mg/kg）into the femoral vein in C57/BL6 mice. Massive hemorrhages were observed in the ischemic area at 1 day after ischemia/reperfusion in tPA-treated mice; however, the hemorrhage was dramatically alleviated when RSG was administered 1 hour before MCAO in the tPA-treated mice ( Figure 1A-B) .
| Statistical analysis
| RSG reduces infarct volume in tPA-infused stroke mice without affecting regional cerebral blood flow
We monitored regional cerebral blood flow during, at 1 hour and 1 day after MCAO by laser speckle 2D imaging ( Figure 2A ). There was no statistical difference in cerebral blood flow during and after MCAO between the two experimental groups, verifying that all animals were subjected to equivalent degree of ischemia and achieved equivalent extent of reperfusion ( Figure 2B ).
Next, we compared the infarct volume which was measured by MAP2 immunohistochemistry and found that RSG treatment significantly reduced the infarct volume in tPA-treated stroke mice 1 day after MCAO (Figure 2C-D) . These results suggest that the combination of RSG with tPA treatment can reduce the ischemic brain infarct compared to tPA-alone-treated stroke mice. Next, we performed a correlation analysis and found that the infarct volume was positively correlated to the hemorrhage area in both experimental groups ( Figure 2E ).
| RSG treatment blocks blood-brain barrier disruption in tPA-infused stroke mice
Considering that BBB disruption is a critical factor that may contribute to the intracerebral hemorrhage, 25, 26 we then explored the effect of RSG on the BBB integrity in the tPA-treated stroke mice. By quantifying the extravasation of plasma-derived IgG, we found that RSG treatment significantly reduced the BBB disruption in stroke mice with tPA thrombolysis ( Figure 3A ,C-D). In addition, we measured the level of tight junction protein ZO-1 using immunofluorescent staining and found that RSG treatment attenuated the disruption of ZO-1 in tPA-treated mice 1 day after MCAO ( Figure 3B ). Next, we did a correlation analysis and found that the BBB disruption (IgG + area and IgG leakage MFI) was positively correlated with HT in both experimental groups ( Figure 3E-F) .
| RSG drives microglial/macrophage polarization in delayed tPA treatment after stroke
It has been suggested that RSG, a PPAR-γ agonist, can drive microglial/macrophage polarization and phenotypic change, 27 which is highly dynamic after ischemic injury. 10 We Figure 5D -E). Collectively, these findings suggest that RSG promotes microglial polarization to the beneficial anti-inflammatory phenotype after ischemia.
| Anti-inflammatory microglia polarization is associated with attenuated tPA-induced HT and BBB disruption after stroke
Considering that RSG may promote anti-inflammatory microglia po- 
| PPAR-γ antagonist GW9662 abolished the protection of RSG against HT and BBB disruption in tPA-infused stroke mice
To further confirm that the protection of RSG against HT and BBB disruption in tPA-treated stroke mice was exerted through activating PPAR-γ, we administered the PPAR-γ antagonist GW9662 (4 mg/ kg) along with RSG 1 hour before MCAO through intraperitoneal injection. We found that GW9662 abolished the protection of RSG against HT and BBB disruption in tPA-treated stroke mice 1 day after stroke (Figure 7A-B) . In addition, GW9662 treatment alone did not significantly alter the BBB disruption after stroke ( Figure 7A-B) . We further analyzed the microglia phenotype and found that the microglia polarization was also reversed by GW9662 treatment together with RSG 1 day after stroke (Figure 7C-G) . These results suggest that RSG exerted its protection against HT and BBB disruption via activating PPAR-γ in tPA-treated stroke mice.
| D ISCUSS I ON
The present study investigated the effect of RSG treatment 1 hour prior to postischemic reperfusion on HT and BBB disruption in stroke mice with tPA thrombolysis. We found that RSG reduced acute brain infarction and attenuated HT and BBB disruption in tPA-treated mice 1 day after stroke. These protective effects of RSG are closely associated with microglia polarization toward the anti-inflammatory phenotype, which may be mediated by activating PPAR-γ. The current finding may pave the way to the development of adjuvant treatment with tPA thrombolysis after stroke in the pursuit of extending the therapeutic window of tPA.
Early reestablishment of cerebral blood flow is crucial for the functional recovery of acute ischemic stroke patients. 28, 29 The latest guideline of acute stroke treatment still recommends tPA as the first-line of effective thrombolytic treatment to achieve early reperfusion of the ischemic brain. 2, 3, 30 However, the current therapeutic window of 4.5 hours after the onset of stroke remarkably limits the clinical use of tPA thrombolysis. [31] [32] [33] BBB disruption is a fundamental pathological feature of intracerebral HT induced by tPA thrombolysis. 34, 35 Loss of BBB integrity results in increased vascular permeability and is associated with reduced cerebral blood flow and impaired hemodynamic responses. 35, 36 Thus, finding a novel strategy to preserve the BBB integrity during tPA thrombolysis is crucial to reduce the risk of intracerebral hemorrhage. It has been shown to exert neuroprotective effects against cerebral ischemic stroke both in animal models and stroke patients. 37 Administration of RSG at the dose of 6 mg/kg 1 hour prior to MCAO could significantly reduce brain infarct at 48 hours after stroke. 23 In order to explore the effect of RSG on the tPA-induced HT after stroke, we injected RSG at the above-mentioned dose and found that RSG significantly reduced hemorrhagic area, IgG extravasation, and tight junction protein degradation.
As a widely used antidiabetic drug which works as an insulin sensitizer by binding to the PPAR-γ in fat cells, RSG may also serve as a master gatekeeper in CNS injury and repair. [37] [38] [39] It is emerging that the PPAR-γ is constitutively expressed in microglia and activating PPAR-γ in microglia may regulate the phenotypic change of microglia. [40] [41] [42] [43] PPAR-γ activation could favor a reprogramming process of microglia toward a beneficial phenotype, with antiinflammatory and tissue-repair properties. [10] [11] [12] [13] 44 Interestingly, previous studies have shown that 1 day after ischemia, the microglia/macrophages adopt an anti-inflammatory phenotype that progressively evolves toward a neurotoxic phenotype at day 7
poststroke. 45 Depletion of monocytes/macrophages increases the ischemic lesion; the ratio of inflammatory/anti-inflammatory macrophages polarization ratio increases early in a mouse model of stroke. 46 In order to address whether the protection of RSG against tPA-induced HT is mediated by its PPAR-γ activating effect, we used the PPAR-γ antagonist GW9662 in combination with RSG in the tPA-treated stroke mice. We found that the therapeutic effect of RSG against tPA-induced HT and BBB disruption was abolished in the presence of GW9662, suggesting a critical role of PPAR-γ activation in the RSG-afforded protection in tPA-induced HT after stroke.
In conclusion, we find that RSG treatment attenuates HT and BBB disruption in tPA-treated stroke mice. The RSG-afforded protective effects on HT and BBB damage are correlated with the microglial polarization toward the anti-inflammatory phenotype and the protection of RSG may be mediated by PPAR-γ activation. 
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